Osteoboost’s State of Bones Report points to gaps in awareness, screening and menopause education as women reach peak risk years.
Osteoboost Health has released its inaugural State of Bones Report, drawing on a survey of 1,053 US women aged 45 to 85 and exploring how women understand, discuss and act on bone health during perimenopause, menopause and later life [1].
The findings suggest that the problem is not indifference. Rather, it is timing. More than half of respondents had never heard of osteopenia, 37.5% did not know menopause and bone loss were connected and nearly half of women over 45 had never had a DEXA scan; in the years when bone loss accelerates most rapidly, the conversation appears to be arriving late, if it arrives at all [1].
Longevity.Technology: Bone health occupies a curious position within the longevity conversation; fundamental to healthy aging, yet frequently overshadowed by newer and more fashionable areas of research. While attention gravitates toward biological age clocks, multiomics and emerging therapeutics, the skeleton continues its quiet work in the background – until, too often, it doesn’t. The findings of Osteoboost’s report suggest that the challenge is not simply one of awareness, but of timing; when people learn about osteopenia, osteoporosis or menopause-related bone loss only after significant decline has occurred, prevention has already surrendered much of its advantage. Modern medicine has an enduring, expensive habit of waiting for structural collapse before offering a solution. It remains profoundly more comfortable treating catastrophic failure than preventing it. Because healthy longevity is entirely predicated on preserving physical independence across decades, the economic and social fallout of this proactive vacuum will inevitably ripple far beyond the clinic.
“I talk to women every day who are shocked to learn that menopause and bone loss are connected. The system fails to properly educate. And then when we do finally reach women, often years too late, we hand them a medication and wonder why they’re hesitant,” said Laura Yecies, CEO of Osteoboost.
“They’re not being difficult. They’re being rational, and they are frustrated. They don’t have enough information to say yes. And that’s not a patient or physician problem. That’s a healthcare system problem [2].”
The missing middle
The report’s most striking findings sit in the space between wellness advice and medical diagnosis. Osteopenia, the clinical precursor to osteoporosis, remains poorly understood despite being a critical window for intervention; according to Osteoboost, 57% of respondents had never heard the term, while 44% of women with a bone-related diagnosis did not know their bone density status [1].
Screening is another point of friction. DEXA scans remain the standard tool for measuring bone density, yet 34% of respondents did not know what a DEXA scan is and half had never had one. Among women who had been scanned, 77.5% said their doctor explained the results clearly, suggesting the failure may not be the consultation itself but the system’s ability to bring women into the diagnostic pathway early enough [1].
An awkward gap. A preventable one.
Menopause as a skeletal inflection point
Bone health is finally breaking out of the narrow silo of reproductive medicine and firmly finding its feet as a part of the broader longevity debate. Menopause is not a discrete event – it is a profound systemic pivot with profound long-term consequences for metabolic stability, physical independence and structural integrity.
Osteoboost’s report found that the knowledge gap was greatest among women in their 50s; among those aged 55 to 59, 74.5% had never heard of osteopenia and 71% had never had a DEXA scan. These are not peripheral years – rather they are the years in which estrogen decline can accelerate bone loss, reshaping risk long before osteoporosis is formally diagnosed [1].
The trust gap also matters. Nearly two-thirds of respondents said they were worried about bone health as they age, but only 31% felt very supported and informed; even more worrying is that 46% of women sampled did not believe bone health is taken as seriously as other women’s health issues such as breast cancer or reproductive health [1].
Evidence and adherence
The report lands alongside growing interest in device-based approaches to early bone health intervention. Osteoboost’s wearable device delivers targeted vibration to the lumbar spine and hips, and has been evaluated in a randomized, sham-controlled trial published in JBMR Plus.
The 12-month trial of postmenopausal women with osteopenia revealed a familiar tension between clinical intent and real-world compliance. While the broad, modified intent-to-treat group missed statistical significance for the primary endpoint of vertebral bone strength, the device delivered for those who actually used it. Participants who hit the adherence threshold of three or more sessions a week saw statistically significant gains in both vertebral strength and volumetric bone mineral density compared with the sham group. Crucially, the therapy was well tolerated, with zero serious device-related adverse events [3].
That distinction is important. For longevity technologies intended for home use, adherence is not a footnote; it is the mechanism by which promising physiology either becomes practical prevention or quietly gathers dust beside the resistance bands.
A harder question
The wider implication is not whether women care about bone health. The report suggests they do. The harder question is whether healthcare systems, employers, clinicians and longevity companies can build the earlier prompts, clearer pathways and better-supported interventions required before skeletal decline announces itself through fracture. Prevention needs choreography. Bone health is asking for the music to start sooner.
Images courtesy of Osteoboost Health
[1] https://www.osteoboost.com/blog/osteoboost-state-of-bones-report-2026
[2] https://www.webwire.com/ViewPressRel.asp?aId=355386
[3] https://academic.oup.com/jbmrplus/advance-article/doi/10.1093/jbmrpl/ziae104/7723941
